ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03139032
Recruitment Status : Terminated (Sponsor decision to terminate the study)
First Posted : May 3, 2017
Last Update Posted : March 27, 2018
Sponsor:
Information provided by (Responsible Party):
Arena Pharmaceuticals

Brief Summary:
The purpose of this phase 2a, proof of concept, open-label clinical study is to evaluate the efficacy and safety of etrasimod (APD334) in inflammatory bowel disease patients with active skin extra-intestinal manifestations.

Condition or disease Intervention/treatment Phase
Inflammatory Bowel Diseases Skin Extra-intestinal Manifestations Drug: APD334 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Proof of concept, open label
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
Actual Study Start Date : July 17, 2017
Actual Primary Completion Date : December 6, 2017
Actual Study Completion Date : December 6, 2017

Arm Intervention/treatment
Experimental: APD334
APD334 active treatment for 12 weeks.
Drug: APD334
APD334 active treatment for 12 weeks.
Other Name: Etrasimod




Primary Outcome Measures :
  1. Exploratory endpoint - Ulcerative Colitis: Change from baseline in stool frequency [ Time Frame: Week 1, 2, 4, 8, and 12 ]
  2. Exploratory endpoint - Ulcerative Colitis: Change from baseline in rectal bleeding [ Time Frame: Week 1, 2, 4, 8, and 12 ]
  3. Exploratory endpoint - Ulcerative Colitis: Change from baseline in Physicians Global Assessments. [ Time Frame: Week 1, 2, 4, 8, and 12 ]
  4. Exploratory endpoint - Crohn's Disease: Change from baseline in disease activity score. [ Time Frame: Week 1, 2, 4, 8, and 12 ]
  5. Exploratory endpoint - Change from baseline in endoscopic improvement/histologic healing using endoscopy or flexible proctosigmoidoscopy. [ Time Frame: Week 12 ]
    Only if there are signs of inflammation at screening another evaluation will be performed at week 12.

  6. Exploratory endpoint - Change from baseline in level of fecal calprotectin. [ Time Frame: Week 4, 8, and 12 ]
  7. Exploratory endpoint - Change from baseline in Physician Global Assessments for active skin extra-intestinal manifestations (PG, EN and psoriasis). [ Time Frame: Week 1, 2, 4, 8, and 12 ]
  8. Exploratory endpoint - Change from baseline in the Dermatology Life Quality Index score. [ Time Frame: Week 1, 2, 4, 8, and 12 ]
  9. Exploratory endpoint - Psoriasis: Change from baseline in Psoriasis Area and Severity Index. [ Time Frame: Week 1, 2, 4, 8, and 12 ]
  10. Exploratory endpoint - Change from baseline in Inflammatory Bowel Disease Questionnaire score. [ Time Frame: Week 2, 4, 8, and 12 ]
  11. Exploratory endpoint - Changes in degree of immune cell infiltration as assessed from skin punch biopsies (from healthy skin and from target lesion). [ Time Frame: Week -1, 8 and 12. ]
    All material collected before treatment and at week 8 or 12.

  12. Exploratory endpoint - Changes in levels of cytokine expression as assessed from skin punch biopsies (from healthy skin and from target lesion). [ Time Frame: Week -1, 8 and 12. ]
    All material collected before treatment and at week 8 or 12.

  13. Exploratory endpoint - Change from baseline in C-reactive protein. [ Time Frame: Week 1, 2, 4, 8, and 12 ]
  14. Exploratory endpoint - Change from baseline in leucocyte characterization. [ Time Frame: Week 1, 2, 4, 8, and 12 ]
  15. Exploratory endpoint - Change from baseline in lymphocyte counts [ Time Frame: Week 1, 2, 4, 8, and 12 ]

Other Outcome Measures:
  1. Safety measured by number of participants with adverse events and abnormal clinical laboratory tests, lymphocyte counts, vital signs, ECG, and other tests (see below). [ Time Frame: Week 12 ]
    • Clinical laboratory tests (chemistry, hematology and urinalysis)
    • Vital sign measurements
    • Physical examination
    • 12-lead electrocardiograms
    • Adverse event reporting
    • Concomitant medication
    • Lymphocyte counts



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female (18-80 years).
  2. Able to provide a signed informed consent prior to any study related procedure being conducted.
  3. Considered to be in stable health in the opinion of the investigator as determined by:

    1. A pre-study physical examination with no clinically significant abnormalities unrelated to IBD.
    2. Vital signs at screening: pulse rate ≥ 55 bpm, systolic blood pressure ≥ 90, and diastolic blood pressure ≥ 55 mmHg.
    3. Liver function tests (ALT/AST, bilirubin and alkaline phosphatase) < 2x the upper limit of normal.
    4. All other pre-study clinical laboratory findings within normal range, or if outside of the normal range are not deemed clinically significant in the opinion of the investigator.
    5. 12-lead electrocardiogram showing no clinically significant abnormalities in the opinion of the investigator (for confirmation please refer to exclusion criterion # 22).
    6. A chest x- ray showing no evidence of active pulmonary disease (a chest x-ray taken within the previous 12 months from the screening visit may also be used).
    7. Ophthalmology evaluation (by an ophthalmologist) without evidence of macular edema, supported with optical coherence tomography where available (dependent on site capability) no later than 3 months prior to screening.
  4. Patients receiving stable treatment for IBD and EIM.
  5. Diagnosis of active psoriasis, erythema nodosum or pyoderma gangrenosum by Investigator assessments. After the enrollment of 10 patients with active EIM, patients with active psoriasis due to anti TNF-alpha therapy can also be included.
  6. Diagnosis of ulcerative colitis or Crohn's disease established prior to screening by clinical and endoscopic evidence.
  7. Eligible male and female patients must agree not to participate in a conception process (i.e. active attempt to let female partner to become pregnant or to impregnate, sperm donation, oocyte donation, in vitro fertilization) for at least 30 days after the last dose of study drug.

Non-sterile patients who are sexually active must take adequate contraception measures.

Exclusion Criteria:

  1. Evidence of abdominal abscess or toxic megacolon at the screening visit.
  2. Patients with history of extensive colitis or pancolitis (duration > 8 years) or left-sided colitis (duration > 12 years) must have documented evidence that a surveillance colonoscopy was performed within 12 months of the initial screening visit (if not, the patient should undergo a colonoscopy in lieu of a flexible proctosigmoidoscopy during screening).
  3. Previous extensive colonic resection (subtotal or total colectomy).
  4. Current evidence of adenomatous colonic polyps that have not been removed.
  5. Current evidence of colonic mucosal dysplasia.
  6. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine or stoma.
  7. Clinical significant infection as judged by the investigator in the previous 6 weeks before enrollment.
  8. Evidence of or treatment for C. difficile infection within 60 days, or other intestinal pathogen within 30 days, prior to randomization.
  9. Exposure to natalizumab or rituximab within 5 half-lives prior to randomization.
  10. Treatment of underlying disease within 30 days prior to randomization (5-ASA, corticosteroids, TNF-alpha inhibitors, probiotics, antidiarrheals, azathioprine and 6-mercaptopurine may be allowed under certain conditions).
  11. Receipt of any investigational agent within 30 days or 5 half-lives (whichever is longer) prior to randomization.
  12. Currently require or are anticipated to require surgical intervention for IBD during the study.
  13. Abnormal (< 80% of predicted values) forced expiratory volume (FEV1) or forced vital capacity (FVC).
  14. Infection with hepatitis C virus anytime in the past; confirmed active infection with hepatitis B virus at screening.
  15. Active or latent tuberculosis (TB), regardless of treatment history, as evidenced by any of the following:

    1. History of TB
    2. A positive diagnostic TB test within one month of randomization
    3. Chest X-ray within 12 months of randomization in which active or latent TB cannot be excluded.
  16. Any known history of congenital or acquired immunodeficiency.
  17. Clinically significant extra-intestinal infection (e.g., pneumonia, pyelonephritis) within 30 days prior to randomization.
  18. Recent history (within 6 months of screening visit) of cardio- or cerebrovascular disease, acute coronary syndrome, myocardial infarction, unstable angina, cerebro-vascular accident, including transient ischemic attack.
  19. Any surgical procedure requiring general anesthesia within 30 days prior to randomization or plans to undergo major surgery during the study period.
  20. History of retinal macular edema.
  21. History of or signs and symptoms of progressive multifocal leukoencephalopathy (PML) as assessed by the PML checklist.
  22. History or presence of cardiac arrhythmia, conduction system disease, or use of Class Ia or Class III anti arrhythmic agents, or baseline QTc ≥ 500 msec.
  23. Infection requiring hospitalization or intravenous antimicrobial therapy, or opportunistic infection within 4 weeks of screening.
  24. History of more than one episode of herpes zoster or any episode of disseminated zoster.
  25. Without documented positive varicella zoster virus (VZV) IgG antibody status or who have completed VZV vaccination within 30 days prior to randomization.
  26. Receipt of live vaccine within 4 weeks prior to screening.
  27. History of lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative disorder, or multiple myeloma.
  28. History of malignancy except for adequately treated basal cell skin cancer.
  29. History of severe allergic or anaphylactic reactions requiring medical attention.
  30. Current or recent history (within one year prior to randomization) of alcohol dependence or illicit drug use.
  31. History of clinically significant leukopenia or lymphopenia at screening.
  32. Active psychiatric problems that, in the investigator's opinion, may interfere with compliance with the study procedures.
  33. History of any clinically significant medical condition that, in the investigator's opinion, would preclude participation in the study.
  34. Use of moderate to strong inhibitors of CYP2C9.
  35. History of severe renal or hepatic impairment.
  36. Inability to attend all the study visits or comply with study procedures.
  37. Prior exposure to etrasimod (APD334).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03139032


Locations
Belgium
Arena 2001
Leuven, Belgium
Germany
Arena 1001
Hamburg, Germany
Serbia
Arena 3001
Belgrade, Serbia
Sponsors and Collaborators
Arena Pharmaceuticals

Responsible Party: Arena Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03139032     History of Changes
Other Study ID Numbers: APD334-006
First Posted: May 3, 2017    Key Record Dates
Last Update Posted: March 27, 2018
Last Verified: March 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Intestinal Diseases
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Gastroenteritis